ViroGates announces a directed issue of nominally 1,547,412 shares, raising approximately DKK 19.3 million
Idag, 07:41
Company Announcement no. 19/2025 (November 18, 2025)
This announcement contains inside information
BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, today announces a directed issue of nominally 1,547,412 shares at DKK 12.45 per share.
The Board of Directors decided at a meeting today to issue nominally 1,547,412 shares, raising approximately DKK 19.3 million in gross proceeds through the directed issue. This issue will be made without pre-emptive rights for existing shareholders and will be carried out by the Board of Directors in accordance with the authorisation in Articles 2.3 and 2.3.1. of the Articles of Association.
The directed share issue will be allocated to a consortium of existing and early investors and an important strategic partner in the Company. The consortium comprises N. P. Louis-Hansen Aps, Ginnerup Capital ApS, and Aetas Healthcare ApS (collectively the “Investors”).
Following the capital increase, the Company’s share capital will increase from nominal DKK 7,737,064 to nominal DKK 9,284,476.
The proceeds are intended to strengthen the company's general capital base and its ability to roll out suPARnostic® to the general health and longevity market.
The shares will be issued at the market price as of the closing date of the Nasdaq First North Growth Market on 17 November 2025 (DKK 12.45 per share).
In preparing the directed issue, the Company’s board of directors has conducted an overall assessment and carefully considered various ways to raise capital. Considering the current circumstances and prevailing market conditions, the board of directors believes that there are reasons to deviate from the shareholders’ pre-emptive subscription right, and that it is in the objective best interest of both the Company and its shareholders to carry out the directed issue and secure the pivotal funding, considering that a rights issue would take significantly longer to complete and would involve an increased risk of an adverse effect on the share price, as seen in several comparable cases with limited exercise of pre-emptive rights and especially considering market volatility and the challenging market conditions.
To secure full subscription in a rights issue, significant underwriting might be required, which would entail significant costs in the current market, with an erosion of the current shareholders’ holdings. A private placement can be carried out at a lower cost and with less complexity than a rights issue. The expenses associated with the private placement are expected to be less than 1% of the gross proceeds.
Registration of the share capital increase will be made as soon as possible. Following registration, the updated Articles of Association will be made available on the Company's website www.virogates.com.
Shares issued in connection with the issue will have the same rights as existing shares under the company's articles of association and are expected to be admitted to trading on Nasdaq First North Growth Market no later than 10 December 2025. The new shares will be issued in the existing ISIN code DK0061030574.
ViroGates will inform the market of the result of the directed issue once it has been completed.
Jakob Knudsen, CEO of ViroGates, says:“The Board and Management of ViroGates welcome the continued commitment from our early investors and established longevity partner. Their support underlines confidence in our technology and in our ambition to expand suPAR testing and will help transition ViroGates into a fully integrated diagnostic and health-technology provider.”
This message is also available here
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and improve hospital patient care. ViroGates markets its blood test products under the suPARnostic® brand.
The Company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (ticker “VIRO”) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
Attachments
20251118 ViroGates Comp Ann 19 Directed Issue Announcement
Ämnen i artikeln
ViroGates announces a directed issue of nominally 1,547,412 shares, raising approximately DKK 19.3 million
Idag, 07:41
Company Announcement no. 19/2025 (November 18, 2025)
This announcement contains inside information
BIRKERØD, DENMARK – ViroGates A/S (“ViroGates” or the “Company”), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, today announces a directed issue of nominally 1,547,412 shares at DKK 12.45 per share.
The Board of Directors decided at a meeting today to issue nominally 1,547,412 shares, raising approximately DKK 19.3 million in gross proceeds through the directed issue. This issue will be made without pre-emptive rights for existing shareholders and will be carried out by the Board of Directors in accordance with the authorisation in Articles 2.3 and 2.3.1. of the Articles of Association.
The directed share issue will be allocated to a consortium of existing and early investors and an important strategic partner in the Company. The consortium comprises N. P. Louis-Hansen Aps, Ginnerup Capital ApS, and Aetas Healthcare ApS (collectively the “Investors”).
Following the capital increase, the Company’s share capital will increase from nominal DKK 7,737,064 to nominal DKK 9,284,476.
The proceeds are intended to strengthen the company's general capital base and its ability to roll out suPARnostic® to the general health and longevity market.
The shares will be issued at the market price as of the closing date of the Nasdaq First North Growth Market on 17 November 2025 (DKK 12.45 per share).
In preparing the directed issue, the Company’s board of directors has conducted an overall assessment and carefully considered various ways to raise capital. Considering the current circumstances and prevailing market conditions, the board of directors believes that there are reasons to deviate from the shareholders’ pre-emptive subscription right, and that it is in the objective best interest of both the Company and its shareholders to carry out the directed issue and secure the pivotal funding, considering that a rights issue would take significantly longer to complete and would involve an increased risk of an adverse effect on the share price, as seen in several comparable cases with limited exercise of pre-emptive rights and especially considering market volatility and the challenging market conditions.
To secure full subscription in a rights issue, significant underwriting might be required, which would entail significant costs in the current market, with an erosion of the current shareholders’ holdings. A private placement can be carried out at a lower cost and with less complexity than a rights issue. The expenses associated with the private placement are expected to be less than 1% of the gross proceeds.
Registration of the share capital increase will be made as soon as possible. Following registration, the updated Articles of Association will be made available on the Company's website www.virogates.com.
Shares issued in connection with the issue will have the same rights as existing shares under the company's articles of association and are expected to be admitted to trading on Nasdaq First North Growth Market no later than 10 December 2025. The new shares will be issued in the existing ISIN code DK0061030574.
ViroGates will inform the market of the result of the directed issue once it has been completed.
Jakob Knudsen, CEO of ViroGates, says:“The Board and Management of ViroGates welcome the continued commitment from our early investors and established longevity partner. Their support underlines confidence in our technology and in our ambition to expand suPAR testing and will help transition ViroGates into a fully integrated diagnostic and health-technology provider.”
This message is also available here
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and improve hospital patient care. ViroGates markets its blood test products under the suPARnostic® brand.
The Company was founded in 2000. Headquartered in Denmark, ViroGates’ sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates’ shares (ticker “VIRO”) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
Attachments
20251118 ViroGates Comp Ann 19 Directed Issue Announcement
Ämnen i artikeln
Techbolagen
Rapporter
Bolånen
.jpg&w=3840&q=75)
Katastrofobligationer
Techbolagen
Mest läst
Rapporter
Bolånen
Katastrofobligationer
Marknadsöversikt
1 DAG %
Senast
1 mån
